Sudarshan Pharma shares rose 7% on Wednesday after the company migrated from BSE’s SME platform to the NSE main board. Its board is scheduled to review Q2 FY27 results and a potential fundraising proposal on October 29.
Sudarshan Pharma shares rose 7% on Wednesday after the company migrated from BSE’s SME platform to the NSE main board. Its board is scheduled to review Q2 FY27 results and a potential fundraising proposal on October 29.
<iframe src="https://hindustansphere.com/embed/cluster/28a2497cef16f6cd702ad255a854b553ede95cd7" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Small-cap stock under ₹50 jumps 7% despite weak trends on Dalal Street; here's why | Target price, stop-loss"></iframe>
